PATENT CLAIM ANALYSIS

Application Number: 16027967
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-12
Patent Classification: ["424", "179100"]

Abstract:
Provided herein are immunoconjugates comprising an anti-ROR1 antibody or an antigen-fragment fragment thereof and a drug moiety. These immunoconjugates are useful for treating ROR1 expressing cancers.

Claim (Index 8):
The immunoconjugate of  claim 1 , wherein the antibody or fragment is covalently bonded to the linker by reaction with a moiety selected from the group consisting of:\n 6-maleimidocaproyl (MC)-VC-PAB; 6-MC-C 6 ; 6-MC-PEG4-VC-PAB-DMEA; 6-MC-PEG4-VA; 6-MC-DPR-VC-PAB; 6-MC-Phe-C 4 -VC-PAB; 6-MC-Phe-C 4 -VC-PAB-DMEA; 6-MC-C 2 -Gly 3 -EDA; dibenzylcyclooctyne (DBCO)-(PEG2-VC-PAB) 2 ; DBCO-PEG4-VC-PAB-DMEA; and N-succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate-VC-PAB.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 95.0
- Lexical Diversity: 1.16667
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['11978122', '14517682', '12939533', '13796768', '15130667']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8203782522673578
- 35 USC 102 Novelty (BERT): 0.5426026719177994
- Combined Prediction Score: 0.792600694232402
- Mean Citation Score: 384.160708
- Max Citation Score: 410.674
- Similarity Product: 280.9848107270002

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test